The Pharmalot View

The Pharmalot View By Ed Silverman

FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’

The Pharmalot View By Ed Silverman

Operation Warp Speed doesn’t have the transparency it needs

The Pharmalot View By Ed Silverman

Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results

The Pharmalot View By Ed Silverman

We shouldn’t rush to use an unproven malaria drug to treat the coronavirus

The Pharmalot View By Ed Silverman

The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?

The Pharmalot View By Ed Silverman

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

The Pharmalot View By Ed Silverman

Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain

The Pharmalot View By Ed Silverman

Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator

The Pharmalot View By Ed Silverman

Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

The Pharmalot View By Ed Silverman

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

The Pharmalot View By Ed Silverman

One of the world’s largest drug makers is paying docs again — and patients are the worse off

The Pharmalot View By Ed Silverman

When modest is actually excessive: AstraZeneca spins its price hikes

The Pharmalot View By Ed Silverman

He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices

The Pharmalot View By Ed Silverman

Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising

The Pharmalot View By Ed Silverman

The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous

The Pharmalot View By Ed Silverman

California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference

The Pharmalot View By Ed Silverman

Here’s how a loophole in a transparency law can distort medical practices

The Pharmalot View By Ed Silverman

This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

The Pharmalot View By Ed Silverman

At $475,000, new cancer drug raises thorny questions about drug pricing — and value

The Pharmalot View By Ed Silverman

Drug makers deserve to be publicly shamed for thwarting competition from generics

The Pharmalot View By Ed Silverman

The art of the deal? Why a money-back guarantee for drugs is a bad idea

The Pharmalot View By Ed Silverman

If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon

The Pharmalot View By Ed Silverman

It’s time to make it legal for Americans to order prescription drugs from abroad

The Pharmalot View By Ed Silverman

US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it

The Pharmalot View By Ed Silverman

The Trump administration could bring down drug prices. But it would take guts